Jan. 13 at 1:04 AM
$CGTX this article explains one of the reasons I think CGTX has struggled to get more support in the AD space. Despite the headline, the article actually leads off by pointing out the SHINE study's "failure." This "failure" hurt the company's image, but c'mon let's be intelligent humans! That same study showed extraordinary results among AD patients with low p-tau217 - and that's important because 30-50% of AD patients fall in that group. Which is still a huge number! Plus, existing treatments like lecanemab and donanemab don't work as well in this population. Plus there's even bigger short term catalysts with DLB. Eventually I think the market will realize all this, but until then us investors will have to wait. Sadly, so will hundreds of thousands of patients who could benefit from zervimesine. Hang in there Cognitians, the market and regulators will eventually realize the value of what is being proven out here. Until then, make the most of each day. https://www.fiercebiotech.com/biotech/cognitions-phase-2-shimmer-results-finally-allow-dementia-drug-shine
